▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Seegene joins hands with China’s Xi’an Tianlong

  • PUBLISHED :October 19, 2018 - 16:19
  • UPDATED :October 19, 2018 - 16:19
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[THE INVESTOR] Korea’s Seegene said on Oct. 19 it has entered into a partnership agreement with in-vitro diagnostics firm Xi’an Tianlong Science and Technology to make a foray into the Chinese market.

Under the pact, the two companies will jointly develop diagnostics tools for diseases showing high market demand such as papillomavirus and sexually transmitted infections.

Seegene will supply reagents that match with diagnostics devices developed by the Chinese partner while Xi’an Tianlong will be in charge of manufacturing, regulatory approval, sales and marketing processes, it said.
The Korean firm plans to accelerate market expansion into China by developing products tailored to the local demand after accumulating experience through the partnership.

“We choose Xi’an Tianlong as a partner as it has strong competitive advantages for market entry into China including its equipment, production and sales networks,” said Chun Jong-yoon, founder and CEO of Seegene.

Founded in 1997, Xi’an Tianlong has three manufacturing plants in Xi’an, Suzhou and Wuxi, with a health care provider network encompassing 300 local firms.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS